India News | Jammu-based Institute Given Nod for Clinical Trials of Anti-cancer Drug: CSIR
Get latest articles and stories on India at LatestLY. The Jammu-based Indian Institute of Integrative Medicine has received approval for clinical trials of its anti-cancer drug IIIM-290, to be used against pancreatic cancer, after successful completion of the preclinical development, the CSIR said on Monday.
New Delhi, Jun 8 (PTI) The Jammu-based Indian Institute of Integrative Medicine has received approval for clinical trials of its anti-cancer drug IIIM-290, to be used against pancreatic cancer, after successful completion of the preclinical development, the CSIR said on Monday.
The IIIM is a constituent of the Council for Scientific and Industrial Research.
Also Read | Nokia 5310 Feature Phone Likely To Be Launched In India Soon; Expected Prices, Features & Specifications.
The approval was given by the New Drugs Division of Central Drugs Standard Control Organisation, the CSIR said in a statement.
"The proposed clinical trial is aimed to assess the safety, tolerability and exposure of the compound in humans along with the early efficacy indicators in pancreatic cancer patients," it added.
This drug was discovered and developed at the natural-products driven drug discovery programme of CSIR-IIIM.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)